CB2 Insights announces key partnership with GL Brands for CBD Trial
CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules when looking to treat anxiety.
Sekar discusses how this trial will be carried out and what the data gained from it will be used for.
Sekar discusses how this trial will be carried out and what the data gained from it will be used for.
People In This Video
No users are tagged in this video